Lataa...
Pertuzumab and trastuzumab: the rationale way to synergy
It has now been 15 years since the HER2-targeted monoclonal antibody trastuzumab was introduced in clinical and revolutionized the treatment of HER2-positive breast cancer patients. Despite this achievement, most patients with HER2-positive metastatic breast cancer...
Tallennettuna:
| Julkaisussa: | Anais da Academia Brasileira de Ciências |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Academia Brasileira de Ciências
2016
|
| Aiheet: | |
| Linkit: | https://www.redalyc.org/articulo.oa?id=32746362012 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|